Loading…
Loading…
JCO (Nuveen Credit Opportunities 2022 Target Term Fund) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how JCO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for JCO and 80,000+ other tickers.
The Nuveen Credit Opportunities 2022 Target Term Fund (JCO) is structured as a closed-end mutual fund, focusing its investments within the fixed income sector. Established by Nuveen Investments, Inc., the fund receives joint oversight from Nuveen Fund Advisors, LLC, and Symphony Asset Management. Its investment strategy primarily targets the United States' fixed income landscape, concentrating on corporate debt instruments such as bonds and senior loans. A critical selection criterion for its holdings is an investment-grade credit rating of at least BBB- from S&P, alongside a specific…
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
American Community Newspapers (OTCMKTS:ACNI - Get Free Report) and Daily Journal Corp. (S.C.) (NASDAQ: DJCO - Get Free Report) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Valuation and Earnings This
Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology.
SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.